n.a. (ARIA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
ARIAD Announces Webcast Of Its Annual Shareholders Meeting

ARIAD Announces Webcast Of Its Annual Shareholders Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Annual Meeting of Stockholders will be webcast live on June 25, 2014 and can be accessed by visiting the investor relations section of the...

Insider Trading Alert - ENTA, REX And ARIA Traded By Insiders

Insider Trading Alert - ENTA, REX And ARIA Traded By Insiders

Stocks with insider trader activity include ENTA, REX and ARIA

ARIAD Pharmaceuticals (ARIA) Is Today's Perilous Reversal Stock

ARIAD Pharmaceuticals (ARIA) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "perilous reversal" (up big yesterday but down big today) candidate

'Fast Money' Recap: Apple Continues to Move Higher

'Fast Money' Recap: Apple Continues to Move Higher

The trading panel discussed Apple, what it unveiled during its developers conference and where the company goes next.

Stocks Recover From Manufacturing Data Snafu as Broadcom Spikes

Stocks Recover From Manufacturing Data Snafu as Broadcom Spikes

The Institute for Supply Management forgot to carry the one when reporting its ISM index for May, sending shares yo-yoing on close-but-not-quite data Monday. Initially reporting a reading of 53.2, the Institute revised the figure to a healthier 55.4 over the month, up from 54.9 in April. That reading gave investors the confidence that manufacturing was expanding at a strong rate after a so-so start to the year.

S&P, Dow Grab Yet Another Record

S&P, Dow Grab Yet Another Record

Stocks surprise with record closes after hugging the flat line for much of the afternoon.

Why Ariad Pharmaceuticals (ARIA) Stock Is Up Today (Update)

Why Ariad Pharmaceuticals (ARIA) Stock Is Up Today (Update)

Ariad Pharmaceuticals (ARIA) rose Monday after the company announced data on ponatinib, or Iclusig, from PACE and Phase 1 clinical trials.

Midday Movers: Biotech Bullishness Trumps Uncertainty Over ISM Numbers: StockTwits.com

Midday Movers: Biotech Bullishness Trumps Uncertainty Over ISM Numbers: StockTwits.com

Investors on StockTwits.com ignored corrected manufacturing data in favor of news from biotech companies.

Apple Conference? Forget It. Biotech Is What Really Matters: StockTwits

Apple Conference? Forget It. Biotech Is What Really Matters: StockTwits

These biotechs are making big waves, as Apple's Worldwide Developers Conference will likely be a washout.

Ariad Pharmaceutical's Iclusig May Relieve Shareholders' Pain: StockTwits

Ariad Pharmaceutical's Iclusig May Relieve Shareholders' Pain: StockTwits

Early clinical trial results for a gastrointestinal cancer drug are spurring investors to buy into Ariad Pharmaceuticals, despite the drug's potentially deadly side effects.

Heavy Early Morning Activity On ARIAD Pharmaceuticals (ARIA)

Heavy Early Morning Activity On ARIAD Pharmaceuticals (ARIA)

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a pre-market mover with heavy volume candidate

Stock Futures See Strong June Start on China Manufacturing Growth

Stock Futures See Strong June Start on China Manufacturing Growth

U.S. stock futures are posting a strong start to June, extending momentum after a May which saw record highs set for both the Dow and S&P 500. Boosting sentiment, strong data out of China indicates the second-largest economy in the world is recovering from recent sluggishness.

ARIAD Announces Longer-Term Safety And Efficacy Data Of Ponatinib From PACE And Phase 1 Clinical Trials

ARIAD Announces Longer-Term Safety And Efficacy Data Of Ponatinib From PACE And Phase 1 Clinical Trials

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced longer-term follow up from its Phase 1 and pivotal Phase 2 trials of Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated ...

ARIAD Announces Initial Data From Phase 2 Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors

ARIAD Announces Initial Data From Phase 2 Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced, for the first time, data from its Phase 2 trial of Iclusig ® ( ponatinib) in adult patients with refractory metastatic and/or unresectable ...

ARIAD Announces Preliminary Safety And Efficacy Data Of Ponatinib In Patients With Newly Diagnosed CML From Discontinued Phase 3 EPIC Trial

ARIAD Announces Preliminary Safety And Efficacy Data Of Ponatinib In Patients With Newly Diagnosed CML From Discontinued Phase 3 EPIC Trial

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced preliminary safety and efficacy data from the discontinued Phase 3 EPIC trial of Iclusig ® ( ponatinib ) vs.

ARIAD Presents Updated Phase 1/2 Data On AP26113 In Patients With ALK+ Non-Small Cell Lung Cancer

ARIAD Presents Updated Phase 1/2 Data On AP26113 In Patients With ALK+ Non-Small Cell Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from...

ARIAD To Present At Upcoming Investor Conferences

ARIAD To Present At Upcoming Investor Conferences

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will provide an overview of the Company’s business at three upcoming investor conferences: The Jefferies Global...

ARIAD Announces Data Presentations And Webcast Of Investor Briefing At The 2014 ASCO Annual Meeting

ARIAD Announces Data Presentations And Webcast Of Investor Briefing At The 2014 ASCO Annual Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical data on Iclusig ® (ponatinib) and AP26113, its investigational oral inhibitor of anaplastic lymphoma kinase (ALK), will be presented at ...

ARIAD To Present At UBS Global Healthcare Conference

ARIAD To Present At UBS Global Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the UBS Global Healthcare Conference being held in New York City.

To Trade or Not to Trade, Part 2.5

There are some good advisors and worthwhile subscription services.

Ariad Pharmaceuticals (ARIA) Stock Falls Despite Revenue Beat

Ariad Pharmaceuticals (ARIA) Stock Falls Despite Revenue Beat

Ariad Pharmaceuticals (ARIA) fell Wednesday despite the company's first-quarter results that beat analysts' expectations.

ARIAD Reports First Quarter 2014 Financial Results And Development Progress

ARIAD Reports First Quarter 2014 Financial Results And Development Progress

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig ® (ponatinib) and licensing agreements.

ARIAD Pharmaceuticals (ARIA) Showing Signs Of Perilous Reversal Today

ARIAD Pharmaceuticals (ARIA) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "perilous reversal" (up big yesterday but down big today) candidate

4 Big Stocks on Traders' Radars

4 Big Stocks on Traders' Radars

Here's a look at how to trade some of the most active stocks on the market today.

Will This Upgrade Help Ariad Pharmaceuticals (ARIA) Stock Today?

Will This Upgrade Help Ariad Pharmaceuticals (ARIA) Stock Today?

Shares of Ariad Pharmaceuticals (ARIA) were upgraded to "buy" from "hold" at Jefferies Group (JEF) this morning, and the stock is up 4.43% to $7.55 in pre-market trade.

Commit To Purchase ARIAD Pharmaceuticals At $4.50, Earn 22.2% Using Options

Commit To Purchase ARIAD Pharmaceuticals At $4.50, Earn 22.2% Using Options

Investors eyeing a purchase of ARIAD Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $7.14/share, might benefit from considering selling puts among the alternative strategies at their disposal.

ARIAD To Webcast Conference Call On First Quarter 2014 Financial Results

ARIAD To Webcast Conference Call On First Quarter 2014 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its first quarter 2014 financial results on Wednesday, May 7, 2014, before the market opens.

ARIAD Pharmaceuticals Inc (ARIA): Today's Featured Health Care Laggard

ARIAD Pharmaceuticals Inc (ARIA): Today's Featured Health Care Laggard

ARIAD Pharmaceuticals was a leading decliner within the health care sector, falling $0.33 (-4.7%) to $6.69 on average volume

FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon?

FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon?

Someone at Novartis screwed up today by sending out a mass email announcing the FDA approval of a new lung cancer drug ceritinib. Brand name: Zykadia. The only problem is FDA hasn't announced the approval of Zykadia yet.

Hugh Cole, Senior Vice President And Chief Business Officer At ARIAD Pharmaceuticals (Photo: Business Wire)

Hugh Cole, Senior Vice President And Chief Business Officer At ARIAD Pharmaceuticals (Photo: Business Wire)

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Hugh M.